Exhibit 99.1

 

LOGO

ALLERGAN REPORTS FOURTH QUARTER 2014 OPERATING RESULTS

(IRVINE, Calif., February 4, 2015) — Allergan, Inc. (NYSE: AGN) today announced operating results for the quarter ended December 31, 2014. Allergan also announced that its Board of Directors has declared a fourth quarter dividend of $0.05 per share, payable on March 20, 2015 to stockholders of record on February 9, 2015.

Operating Results Attributable to Stockholders from Continuing Operations

For the quarter ended December 31, 2014:

 

 

Allergan reported $1.77 diluted earnings per share attributable to stockholders compared to $1.04 diluted earnings per share attributable to stockholders for the fourth quarter of 2013.

 

 

Allergan reported $2.17 non-GAAP diluted earnings per share attributable to stockholders compared to $1.35 non-GAAP diluted earnings per share attributable to stockholders for the fourth quarter of 2013, a 60.7 percent increase.

Product Sales

For the quarter ended December 31, 2014:

 

 

Allergan reported $1,889.0 million total product net sales. Total product net sales increased 13.8 percent, or 17.2 percent on a constant currency basis, compared to total product net sales in the fourth quarter of 2013.

 

   

Total specialty pharmaceuticals net sales increased 12.4 percent, or 15.3 percent on a constant currency basis, compared to total specialty pharmaceuticals net sales in the fourth quarter of 2013.

 

   

Total core medical devices net sales increased 20.7 percent, or 26.9 percent on a constant currency basis, compared to total core medical devices net sales in the fourth quarter of 2013.

“Allergan yet again recorded in the fourth quarter the strongest increase in absolute dollar sales in any quarter in our history driven by exceptional performance across all of our businesses and geographic regions. This is a tribute to the focus of our employees during the unsolicited acquisition attempt,” said David E.I. Pyott, Allergan’s Chairman of the Board and Chief Executive Officer. “Furthermore, we are excited about the acquisition by Actavis, with the vision of creating the most dynamic company in a new category of Growth Pharma companies.”

 

Page 1 of 15


The following information was filed by Allergan Inc on Wednesday, February 4, 2015 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Allergan Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Allergan Inc.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account